Los Angeles Capital Management LLC Trims Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Los Angeles Capital Management LLC lessened its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 19.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 63,774 shares of the biopharmaceutical company’s stock after selling 15,498 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Dynavax Technologies were worth $892,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale purchased a new position in shares of Dynavax Technologies during the third quarter worth approximately $33,000. Advisor Resource Council acquired a new position in Dynavax Technologies in the fourth quarter valued at $144,000. Rathbones Group PLC acquired a new position in Dynavax Technologies in the third quarter valued at $158,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Dynavax Technologies in the fourth quarter valued at about $209,000. Finally, AlphaMark Advisors LLC acquired a new stake in shares of Dynavax Technologies during the fourth quarter worth about $230,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on DVAX. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research note on Thursday. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. The Goldman Sachs Group initiated coverage on shares of Dynavax Technologies in a research note on Thursday, February 1st. They issued a “neutral” rating and a $20.00 price objective on the stock. Finally, StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Friday, April 26th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.33.

Insider Buying and Selling

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $12.78, for a total value of $262,322.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.98% of the stock is owned by insiders.

Dynavax Technologies Stock Down 5.5 %

DVAX opened at $11.01 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 13.81 and a quick ratio of 12.96. Dynavax Technologies Co. has a 12 month low of $10.48 and a 12 month high of $15.15. The stock has a market capitalization of $1.44 billion, a P/E ratio of -183.50 and a beta of 1.30. The business has a 50 day simple moving average of $12.02 and a 200-day simple moving average of $13.01.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.